Who are AZD9833 with anastrozole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PF-07850327, ARV-471, vepdegestrant, BGB-16673, CKD-843 dose#1, Placebo + fulvestrant, Placebo,Fulvestrant,Goserelin acetate, AZD9833.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd9833-with-anastrozole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AZD9833 with anastrozole — Competitive Intelligence Brief

AZD9833 with anastrozole (AZD9833 with anastrozole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SERD. Area: Oncology.

phase 1 SERD Estrogen receptor alpha (ERα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD9833 with anastrozole (AZD9833 with anastrozole) — AstraZeneca. Estrogen receptor inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD9833 with anastrozole TARGET	AZD9833 with anastrozole	AstraZeneca	phase 1	SERD	Estrogen receptor alpha (ERα)
PF-07850327, ARV-471, vepdegestrant	pf-07850327-arv-471-vepdegestrant	Pfizer	marketed	Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)	Estrogen Receptor (ER)
BGB-16673	BGB-16673	BeOne Medicines	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-843 dose#1	CKD-843 dose#1	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Placebo + fulvestrant	Placebo + fulvestrant	Nanjing Chia-tai Tianqing Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Placebo,Fulvestrant,Goserelin acetate	Placebo,Fulvestrant,Goserelin acetate	Ahon Pharmaceutical Co., Ltd.	phase 3	Selective estrogen receptor degrader (SERD) + GnRH agonist combination	Estrogen receptor (ER) + GnRH receptor
AZD9833	AZD9833	AstraZeneca	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor Alpha (ESR1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SERD class)

AstraZeneca · 2 drugs in this class
Xuanzhu Biopharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD9833 with anastrozole — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9833-with-anastrozole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab